Lengthy and Variable Delays in Oncology Drug Coverage Determination

Author:

Haque Waqas1,Rana Iemaan23,Zahid Sohail1,Hsiehchen David4

Affiliation:

1. New York University Langone, New York

2. University of Illinois Chicago College of Medicine, Chicago

3. Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley

4. Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas

Abstract

This cohort study examines the variability in time to pharmacy and therapeutics committees’ determinations of coverage of approved oncology drugs across multiple payers.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference4 articles.

1. Medicare’s enduring struggle to define “reasonable and necessary” care.;Neumann;N Engl J Med,2012

2. The changing roles of P&T committees: a look back at the last decade and a look forward to 2020.;Vogenberg;P T,2014

3. Coverage of new drugs in Medicare Part D.;Naci;Milbank Q,2022

4. Coverage of novel therapeutic agents by Medicare prescription drug plans following FDA approval.;Shaw;J Manag Care Spec Pharm,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3